DelveInsight's RET Fusion Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Gene fusions, which arise from chromosomal rearrangements, are recognised as a significant driver of oncogenesis. They result in chimeric transcripts that can encode novel protein functions, ...

The FDA granted accelerated approval to the bispecific antibody zenocutuzumab (Bizengri) for NRG1 gene fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) on Wednesday.

The US Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus) as an intravenous infusion for the treatment of certain adults with non-small cell ...

Identification of specific gene fusions is critical for the successful targeted treatment of pediatric cancer patients. Researchers at Children's Hospital Los Angeles have developed a novel assay that ...

Despite decades of progress in pediatric oncology, outcomes for children with high-risk or recurrent rhabdomyosarcoma (RMS) remain discouragingly low. While some patients with intermediate-risk ...

BUFFALO, N.Y., — Many childhood cancers start with a hijacking at the molecular level. A group of abnormal proteins known as fusion proteins aberrantly engage with a collection of proteins that ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc. (Arima), a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, ...

Using a novel bioinformatics approach, researchers found that the majority of prostate cancers carry a specific gene fusion, a common feature of blood cancers but relatively rare in solid tumors, ...

The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and encouraging clinical trial outcomes. With the approval ...